Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX24.533,08+1,21 %

Gold3.310,65+0,30 %

Öl (Brent)69,94-0,26 %

Dow Jones44.326,67+0,20 %

US Tech 10022.799,78+0,44 %

EUR/USD1,17165-0,07 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Lyell Immunopharma Aktie

Aktie

ISIN: US55083R1041 WKN: A3CSFF SYM: LYEL Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,4367

USD

+8,74 %

+0,0351 USD

Letzter Kurs 31.05.25 UTP Consolidated

Lyell Immunopharma Aktie kaufen

Geldkurs

30.05.25

0,4286

USD

300 STK

Briefkurs

30.05.25

0,4299

USD

2.000 STK

BEI SMARTBROKER+ HANDELN

Hinweis
Verlängerte Handelszeiten
Ab sofort von 07:30 bis 23:00 Uhr

Baader Tragding

Neueste Nachrichten

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series 23.06.25 · globenewswire · Lyell Immunopharma
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma 17.06.25 · globenewswire · Lyell Immunopharma
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments 09.06.25 · globenewswire · Lyell Immunopharma
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference 04.06.25 · globenewswire · Lyell Immunopharma
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 13.05.25 · globenewswire · Lyell Immunopharma
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma 15.04.25 · globenewswire · Lyell Immunopharma
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 11.03.25 · globenewswire · Lyell Immunopharma
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences 18.02.25 · globenewswire · Lyell Immunopharma
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference 09.01.25 · globenewswire · Lyell Immunopharma
bit.bio Raises $30 Million Led by M&G Investments to Focus on Tools for the Research, Drug Discovery and Cell Therapy Markets 16.12.24 · PR Newswire (engl.) · Illumina
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting 10.12.24 · globenewswire · Lyell Immunopharma
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting 05.11.24 · globenewswire · Lyell Immunopharma

1
2

Meistgelesen

30 Tage
12 Monate

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive ... 148 Leser
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series 120 Leser
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable ... 116 Leser

Lyell Immunopharma Announces Participation in September Investor Conferences 452 Leser
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 296 Leser
bit.bio Raises $30 Million Led by M&G Investments to Focus on Tools for the Research, Drug ... 280 Leser
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive ... 148 Leser
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP ... 140 Leser
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for ... 132 Leser
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences 128 Leser
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series 120 Leser
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the ... 116 Leser
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation ... 116 Leser